Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:4/6/2019
Start Date:October 9, 2018
End Date:June 18, 2023

Use our guide to learn which trials are right for you!

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

This phase II trial studies how well axitinib and nivolumab works in treating participants
with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread
to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in
treating participants with TFE/translocation renal cell carcinoma.

PRIMARY OBJECTIVES:

I. To establish the clinical activity of axitinib and/or nivolumab therapy for advanced
transcription factor E3/translocation morphology renal cell carcinoma (TFE/tRCC).

SECONDARY OBJECTIVES:

I. To further define the toxicities of the study arms in the treatment of translocation
morphology RCC across all ages.

EXPLORATORY OBJECTIVES:

I. To characterize tRCC clinical behavior across all age groups. II. To evaluate type of
antitumor immune response and stability of T cell activation before and after treatment with
immunotherapy or antiangiogenic therapy.

III. To develop a tumor bank of tRCC tumor samples treated on study for further biological
investigations.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM A: Participants receive axitinib orally (PO) twice daily (BID) on days 1-28 and nivolumab
intravenously (IV) over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for
up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.

ARM B: Participants receive axitinib PO BID on days 1-28. Treatment repeats every 28 days for
up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.

ARM C: Participants receive nivolumab IV over 30-60 minutes on days 1 and 15. Treatment
repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, participants are followed up every 3 months for 1 year,
every 4 months for 1 year, every 6 months for 2 years. Follow-up at year 5 and beyond is at
the discretion of the treating physician.

Inclusion Criteria:

- Patients must have a body surface area (BSA) >= 0.53 m^2

- Histologically confirmed unresectable or metastatic translocation morphology renal
cell carcinoma diagnosed using World Health Organization (WHO)-defined criteria.
Patients may be newly diagnosed or have received prior cancer therapy

- Patients must have had histologic verification of the malignancy

- Patients must have measurable disease, documented by clinical, radiographic, or
histologic criteria as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version (v)1.1

- Patients must have a tumor showing the appropriate morphologic appearance, and
either confirmed TFE3 nuclear protein expression by immunohistochemistry with
appropriate positive and negative controls performed at a Clinical Laboratory
Improvement Act (CLIA)-certified laboratory, or evidence of TFE3 or TFEb
translocation by either fluorescence in situ hybridization (FISH) or reverse
transcriptase- polymerase chain reaction (RT-PCR) performed at a CLIA-certified
laboratory. For TFE3 immunohistochemistry, any nuclear positivity in the presence
of appropriate positive and negative controls should be considered as evidence of
TFE3 immunohistochemical expression. NOTE: If the institution is unable to
perform these studies, unstained slides may be submitted to Dr. Elizabeth
Perlman, who will perform TFE3 analysis at no charge. The slide will be returned
to the referring institution for local evaluation, to be included in their
institutional report

- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age

- Patients must have a life expectancy of >= 8 weeks

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry
onto this study (6 weeks if prior nitrosourea)

- Immunotherapy: Must not have received within 4 weeks of entry onto this study

- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
with a biologic agent

- Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6
months must have elapsed if prior craniospinal RT or if >= 50% radiation of
pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM)
radiation

- Prior therapy with tyrosine kinase inhibitors (TKIs) that have no known activity
against VEGFR1-3 are permitted

- Peripheral absolute neutrophil count (ANC) >= 1000/uL

- Platelet count >= 75,000/uL (transfusion independent)

- Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)

- Urine protein: =< 30 mg/dL in urinalysis or =< 1+ on dipstick, unless quantitative
protein is < 1000 mg in a 24 hours (h) urine sample

- For patients < 18 years of age: Serum creatinine =< 1.5 X upper limit of normal (ULN),
or measured or calculated creatinine clearance or radioisotope glomerular filtration
rate (GFR) >= 60 mL/min/1.73 m^2 for patient with creatinine levels > 1.5 X
institutional ULN, or a serum creatinine based on age/gender as follows:

- 1 to < 2 years - 0.6 mg/dL (male, female)

- 2 to < 6 years - 0.8 mg/dL (male, female)

- 6 to < 10 years - 1 mg/dL (male, female)

- 10 to < 13 years - 1.2 mg/dL (male, female)

- 13 to < 16 years - 1.5 mg/dL (male), 1.4 mg/dL (female)

- >= 16 years - 1.7 mg/dL (male), 1.4 mg/dL (female)

- For patients >= 18 years of age: Serum creatinine =< 2 X ULN, or measured or
calculated creatinine clearance or radioisotope GFR >= 40 mL/min/1.73 m^2 for patient
with creatinine levels > 2 X institutional ULN

- Serum total bilirubin =< 1.5 X ULN for age, or direct bilirubin =< ULN for patients
with total bilirubin levels > 1.5 X ULN

- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 X
ULN for age

- Albumin > 2.5 mg/dL

- Shortening fraction of >= 27% by echocardiogram, or

- Ejection fraction of >= 50% by radionuclide angiogram

- No history of myocardial infarction, severe or unstable angina, or peripheral vascular
disease

- Corrected QT (QTc) =< 480 msec. Note: Patients with grade 1 prolonged QTc (450-480
msec) at the time of study enrollment should have correctable causes of prolonged QTc
addressed if possible (i.e., electrolytes, medications)

- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN. However,
if patient is receiving anticoagulant therapy, PT or partial thromboplastin time (PTT)
should be within therapeutic range of intended use of anticoagulants

- Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless patient is receiving
anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
of anticoagulants

- A baseline blood pressure (BP) =< the 95th percentile for age, height, and gender for
patients < 18 years old, or =< 150 mmHg (systolic) and =< 90 mmHg (diastolic) for
patients >= 18 years old

- Note: 2 serial blood pressures should be taken at least 1 hour apart and averaged
to determine baseline BP

- Patients are eligible if on stable doses (>= 7 days) of anti-hypertensive medications
with a baseline BP meeting the criteria above

Exclusion Criteria:

- Patients unable to swallow whole tablets

- Patients who in the opinion of the investigator are not able to comply with the study
procedures are not eligible

- Prior Therapy

- Patients who have received prior therapy with axitinib or nivolumab or other VEGF
or PD1/PD-L1 targeted therapies

- Patients with hypersensitivity to axitinib, nivolumab, or any of its excipients

- Patients who previously received an allogeneic stem cell transplant (SCT) or
solid organ transplant are not eligible

- Patients may not be receiving any other investigational agents (within 4 weeks
prior to study enrollment)

- Patients who have received prior anti-cancer monoclonal antibody (mAb) within 4
weeks prior to study enrollment or who have not recovered (i.e., =< grade 1 or at
baseline) from adverse events due to agents administered more than 4 weeks prior
to enrollment

- Surgery: Patients who have had or who are planning to have the following invasive
procedures are not eligible:

- Major surgical procedure, laparoscopic procedure, open biopsy, core biopsy,
fine needle aspirate, or significant traumatic injury within 7 days prior to
enrollment. NOTE: External central lines must be placed at least 3 days
prior to planned treatment initiation and subcutaneous ports must be placed
at least 7 days prior to planned treatment initiation

- Patients who have a serious or non-healing wound or ulcer at the time of
study enrollment are not eligible

- Patients who have a history of abdominal fistula, gastrointestinal perforation,
or intra-abdominal abscess within 28 days of study enrollment are not eligible

- Patients who have received prior targeted small molecule therapy within 2 weeks
of enrollment or have not recovered (i.e., =< grade 1 or at baseline) from
adverse events due to agents administered more than 4 weeks prior to enrollment.
NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and
may qualify for the study

- Pre-existing conditions, which may include:

- Additional known malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin, or squamous cell carcinoma
of the skin that has undergone potentially curative therapy, or in situ cervical
cancer

- Patients with underlying immune deficiency, chronic infections including
hepatitis, tuberculosis (TB), or autoimmune disease

- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial

- Patients with underlying hematologic issues including congenital bleeding
diathesis, known previous gastrointestinal (GI) bleeding requiring intervention
within the past 6 months, history of hemoptysis within 42 days prior to study
enrollment, active pulmonary emboli, or deep vein thromboses (DVT) that are not
stable on anticoagulation regimen

- Patients must not have had significant vascular disease (i.e. Moya-Moya, aortic
aneurysm requiring surgical repair)

- A known history of, or any evidence of active, non-infectious pneumonitis

- Patients with known active central nervous system (CNS) metastases and/or
carcinomatous meningitis or leptomeningeal disease. Patients with previously
treated brain metastases may participate provided they are stable (without
evidence of progression by imaging for at least 4 weeks prior to study enrollment
and any neurologic symptoms have returned to baseline), have no evidence of new
or enlarging brain metastases, and are not using steroids for at least 7 days
prior to study enrollment. This exception does not include carcinomatous
meningitis which is excluded regardless of clinical stability

- Any uncontrolled, intercurrent illness including but not limited to ongoing or
active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia

- Any serious medical or psychiatric illness/condition including substance use
disorders likely in the judgment of the investigator(s) to interfere or limit
compliance with study requirements/treatment

- Patients with active autoimmune disease that has required systemic treatment in
the past 2 years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment

- Treatments and/or medications the patient is receiving or has received that would make
her/him ineligible, including:

- Concomitant (or receipt of) treatment with medications that may affect the
metabolism of nivolumab and/or axitinib within 7 days prior to planned first dose
of protocol therapy

- A live vaccine within 30 days of planned first dose of protocol therapy. NOTE:
Inactivated flu vaccines are allowed; however intranasal influenza vaccines
(e.g., Flu-Mist) are live attenuated vaccines, and are not allowed

- Pregnancy and breast feeding

- Due to risks of fetal and teratogenic adverse events as seen in animal studies, a
negative pregnancy test must be obtained in females of childbearing potential,
defined as females who are post-menarchal. If the urine test is positive or
cannot be confirmed as negative, a serum pregnancy test will be required

- Females of childbearing potential that are sexually active must agree to either
practice 2 medically accepted highly-effective methods of contraception at the
same time or abstain from heterosexual intercourse from the time of signing the
informed consent through 5 months after the last dose of study drug

- Lactating females are not eligible unless they have agreed not to breastfeed
their infants starting with the first dose of study therapy through 5 months
after the last dose of study therapy

- Male patients must agree to use an adequate method of contraception starting with the
first dose of study therapy through 7 months after the last dose of study therapy.
Prior history of vasectomy does not replace requirement for contraceptive use

- Regulatory requirements

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer
Institute (NCI) requirements for human studies must be met
We found this trial at
188
sites
Lexington, Kentucky 40504
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lexington, KY
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
(512) 324-0000
Principal Investigator: Amy C. Fowler
Dell Children's Medical Center of Central Texas Welcome to Dell Children
?
mi
from
Austin, TX
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Matthew A. Kutny
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: James I. Geller
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-1000
Principal Investigator: John J. Letterio
Phone: 216-844-5437
Rainbow Babies and Children's Hospital UH Rainbow Babies & Children’s Hospital is a 244-bed, full-service...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Michael S. Isakoff
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Anderson (Andy) B. Collier
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Sara E. Helmig
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Eric J. Lowe
Children's Hospital of The King's Daughters Children
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Elyssa M. Rubin
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
530 Northeast Glen Oak Avenue
Peoria, Illinois 61603
(309) 624-4945
Principal Investigator: Jaime M. Libes
Phone: 888-226-4343
Saint Jude Midwest Affiliate The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic was...
?
mi
from
Peoria, IL
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Frank M. Balis
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Andrew Bukowinski
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Linda C. Stork
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
7700 Floyd Curl Dr
San Antonio, Texas 78229
(210) 575-7000
Principal Investigator: Vinod K. Gidvani-Diaz
Methodist Children's Hospital of South Texas Methodist Children
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Anne-Marie R. Langevin
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Robert M. Cooper
Phone: 800-398-3996
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Laura Sedig
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Douglas J. Scothorn
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Brandon D. Bernard
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Jason M. Fixler
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Robert M. Cooper
Phone: 800-398-3996
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Elizabeth A. Mullen
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Stuart H. Gold
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Ashley E. Meyer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Ami V. Desai
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Rabi Hanna
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: John J. Letterio
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: David M. King
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Corbin, Kentucky 40701
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Corbin, KY
Click here to add this to my saved trials
Council Bluffs, Iowa 51503
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Creston, Iowa 50801
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Creston, IA
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
Dayton, Ohio 45404
Principal Investigator: Ayman A. El-Sheikh
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
?
mi
from
Denver, CO
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Durango, CO
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Durango, CO
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
?
mi
from
Edina, MN
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Enumclaw, Washington 98022
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Enumclaw, WA
Click here to add this to my saved trials
Federal Way, Washington 98003
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Federal Way, WA
Click here to add this to my saved trials
Fontana, California 92335
Principal Investigator: Robert M. Cooper
Phone: 800-398-3996
?
mi
from
Fontana, CA
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Kelly L. Vallance
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
550 Osborne Rd NE
Fridley, Minnesota 55432
(763) 236-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Unity Hospital Unity Hospital is one of the Twin Cities
?
mi
from
Fridley, MN
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: William B. Slayton
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Golden, CO
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
2460 West Horizon Ridge Parkway
Henderson, Nevada 89052
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Hixson, Tennessee 37343
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Hixson, TN
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
(808) 983-6000
Principal Investigator: Wade T. Kyono
Phone: 808-983-6090
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Najat C. Daw
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mariko Sato
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Kearney, Nebraska 68845
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Kearney, NE
Click here to add this to my saved trials
Kearney, Nebraska 68847
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Kearney, NE
Click here to add this to my saved trials
2018 W Clinch Ave
Knoxville, Tennessee 37916
(865) 541-8000
Principal Investigator: Ray C. Pais
Phone: 865-541-8266
East Tennessee Children's Hospital East Tennessee Children's Hospital is a not-for-profit, private, independent pediatric medical...
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lakewood, Colorado 80228
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Lakewood, Colorado 80228
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Lakewood, Washington 98499
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lakewood, WA
Click here to add this to my saved trials
1111 Shadow Lane
Las Vegas, Nevada 89102
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
6827 West Tropicana Avenue
Las Vegas, Nevada 89103
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89106
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89106
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89113
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89119
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89121
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89182
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials